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Original article
The iCanCope pain self-management application for
adolescents with juvenile idiopathic arthritis: a pilot
randomized controlled trial

CL IN IC A L
SC I E NC E

Abstract
Objectives. To evaluate the feasibility and preliminary effectiveness of iCanCope with Pain (iCanCope), a
smartphone-based pain self-management program, in adolescents with JIA. iCanCope featured symptom tracking,
goal-setting, pain coping skills and social support.
Methods. A two-arm pilot randomized controlled trial was used to evaluate the iCanCope app compared with a
version with symptom tracking only. Primary (feasibility) outcomes were: participant accrual/attrition rates, success
of app deployment, acceptability and adherence. Secondary (preliminary effectiveness) outcomes were: pain intensity, pain-related activity limitations and health-related quality of life. Outcomes were assessed at baseline and
8 weeks. Adherence was defined as the proportion of completed symptom reports: ‘low’ (24%); ‘low-moderate’
(25–49%); ‘high-moderate’ (50–75%); or ‘high’ (76–100%). Linear mixed models were applied for preliminary effectiveness analyses as per intention-to-treat.
Results. Adolescents (N ¼ 60) were recruited from three paediatric rheumatology centres. Rates of accrual and
attrition were 82 and 13%, respectively. Both apps were deployed with high success (over 85%) and were rated
as highly acceptable. Adherence was similar for both groups, with most participants demonstrating moderate-tohigh adherence. Both groups exhibited a clinically meaningful reduction in pain intensity (1 point) that did not
statistically differ between groups. There were no significant changes in activity limitations or health-related quality
of life.
Conclusion. The iCanCope pilot randomized controlled trial was feasible to implement in a paediatric rheumatology setting. Both apps were deployed successfully, with high acceptability, and were associated with moderate-tohigh adherence. Preliminary reductions in pain intensity warrant a future trial to evaluate effectiveness of iCanCope
in improving health outcomes in adolescents with JIA.
Trial registration. ClinicalTrials.gov identifier: NCT02764346.
Key words: juvenile idiopathic arthritis, pain, self-management, smartphone, pilot randomized controlled trial
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Pilot randomized controlled trial

Rheumatology key messages
The iCanCope pilot randomized controlled trial was feasibly implemented in a paediatric rheumatology setting.
. The iCanCope self-management app for JIA pain is highly acceptable and associated with moderate-to-high
adherence.
. Clinically meaningful reductions in pain intensity warrant a larger iCanCope trial in adolescents with JIA.
.

Introduction

https://academic.oup.com/rheumatology

Methods
Trial design
A two-arm parallel group pilot randomized controlled
trial design was used to compare the iCanCope smartphone intervention condition with a smartphone-based
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JIA is the most common paediatric rheumatic disease,
affecting approximately 1 in 1000 children [1, 2]. The
disease course may involve flares of increased disease
activity or chronic joint inflammation, which can persist
into adulthood [3, 4]. As described by a synthesis of
qualitative studies, ‘JIA can have a debilitating impact
on children and adolescents. Patients must contend
with unpredictable phases of incapacitating pain, stigmatization, and physical limitations’ (p. 1403) [5].
Pain is reported as the most common and distressing
symptom of JIA [2]. This pain is known to negatively affect all aspects of health-related quality of life (HRQL),
including physical, emotional, social and role functioning
[6]. Seventy-seven percent of North American paediatric
rheumatologists acknowledge that youth with JIA continue to experience clinically significant pain despite adequate doses of anti-inflammatory and diseasemodifying therapy [7]. Even a small reduction in pain is
associated with improved HRQL in JIA patients [8].
Self-management can be defined as ‘the individual’s
ability to manage the symptoms, treatment, physical,
and psychological consequences and lifestyle changes
inherent to living with a chronic illness’ [9]. As children
mature, they are expected to assume increasing responsibility for disease self-management [10]. However, adherence to JIA disease management is typically
suboptimal [11–13]. Improved self-management early in
the disease trajectory may help to improve health outcomes, including pain.
Digital technologies have shown promise in improving
the accessibility and availability of education, psychosocial interventions and social support for adolescents
with JIA [14, 15]. There is also preliminary evidence that
self-management interventions can improve symptoms
and health status in other childhood illnesses [16].
Smartphones are particularly well-suited to deliver selfmanagement support to adolescents due to their widespread adoption, powerful technical capabilities and
deep integration into daily routine [17, 18].
iCanCope with Pain (iCanCope) is a smartphonebased program that was developed to meet the need
for an accessible, evidence-based self-management
program for youth with persistent pain. iCanCope was
created through a phased, user-centred design approach. In phase 1A, a qualitative needs assessment
was completed in adolescents with persistent pain and
health-care providers [19]. In phase 1B, a scoping

review demonstrated that publicly available ’pain apps’
lack: (i) comprehensive pain self-management content,
(ii) engagement of patients, (iii) consultation with healthcare professionals, (iv) a theoretical basis for content or
design, and (v) none were focused on JIA [20]. In phase
2A, group design sessions were held with end users
(adolescents with different types of persistent pain,
including JIA), app designers and members of the research team. In phase 2B, a prototype app was
designed by a team of professional designers and
human factors specialists. The prototype then underwent iterative cycles of usability testing with a sample of
15 young people with persistent pain to ensure that it
was easy to use and was perceived as valuable [21].
The final iCanCope intervention app (iOS/Android)
includes features of symptom tracking, goal setting, library of disease education and pain coping strategies,
and peer-based social support (supplementary Fig. S1,
available at Rheumatology online). A symptom trackingonly version of iCanCope (iOS/Android) was also developed for use in this trial as an attention-control condition
(see Study conditions).
This study was focussed on evaluating the feasibility
and preliminary effectiveness of the iCanCope pain selfmanagement program in adolescents with JIA.
The primary objective was to determine whether the
iCanCope program could be feasibly implemented as
planned. The specific feasibility outcomes were: participant accrual and attrition rates; success of app deployment; acceptability of the study conditions; and
adherence of adolescents with JIA to daily symptom
tracking on a smartphone app, with and without the
presence of other self-management features.
The secondary objective was to determine whether
use of iCanCope by adolescents with JIA aged
12–18 years leads to differences in pain intensity, painrelated activity limitations and HRQL after 8 weeks,
compared with a symptom tracking condition.
The exploratory objective was to characterize how
adolescents with JIA engage with the intervention and
attention-control versions of the iCanCope app.
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duration. Disease activity was measured through a
baseline Physician Global Assessment [25]. The
Physician Global Assessment assesses current disease
activity on a 0–10 NRS with the anchors of ‘no activity’
and ‘maximum activity’.

Participants

Implementation outcomes

Adolescents were recruited in person from three
Canadian paediatric rheumatology centres. Adolescents
were eligible to participate if they were: (i) aged between
12 and 18 years, (ii) diagnosed with JIA as per their
rheumatologist [22], (iii) able to speak and read English,
(iv) experiencing average arthritis-related pain in the
past week of >3 on a 0–10 numerical rating scale (NRS)
as per self-report, (v) able to complete online outcome
measures via home computer or tablet and (vi)able to
have daily access to a smartphone (iPhone or Android).
Adolescents were excluded if they: (i) were already
enrolled in another JIA intervention study, and/or (ii) had
major comorbid illnesses or cognitive impairments that
could affect their ability to use and understand the
iCanCope program as per their healthcare provider,
and/or (iii) took part in a previous iCanCope
study. Participants received gift cards (total value
CAD$70) in recognition of their time and commitment to
the study.

.

Study conditions
Participants were randomized to receive one of two
possible study apps (see Table 1). The intervention condition was a version of the iCanCope app that included
symptom tracking as well as other self-management
features. The control condition was a version of
iCanCope that included symptom tracking features only.
This condition was designed to control for the potential
effects on outcomes of time, attention from the research
team (including app orientation and study communication) and smartphone-mediated symptom tracking during the study period.

Participant accrual and attrition rates were calculated
based on data from coordinator tracking logs.
. Successful app deployment, defined as installing and
logging into the assigned app, was calculated based on
data from coordinator tracking logs.
. Acceptability of the assigned iCanCope app was measured using the Acceptability e-Scale [26]. This tool uses
5-point Likert scales where a higher score indicates
higher acceptability. The range of possible acceptability
scores was 8 to 40.
. Adherence was measured using the Analytics Platform
for Evaluating Effective Engagement (APEEE) [27], a
proprietary analytics software. APEEE was used to capture number of symptom Check-Ins completed and
interaction with the History feature.
Preliminary effectiveness outcomes
Pain intensity was measured using an 11-point NRS
with the anchors of 0 (‘no pain’) and 10 (‘most pain possible’) [28]. This scale assesses usual level of pain in the
past 7 days.
. Pain-related activity limitations was measured using the
Child Activity Limitations Interview (CALI-21) [29]. The
CALI-21 assesses functional impact of persistent pain.
Respondents rate their level of difficulty with 21 different activities over the past 4 weeks because of pain.
Each item is rated on a 5-point NRS ranging from 0 ‘not
very difficult’ to 4 ‘extremely difficult’. The range of possible CALI-21 scores was 0–80.
. HRQL was measured using the PedsQL 3.0 Arthritis
Module [30]. This tool assesses problems with pain and
hurt, daily activities, treatment, worry and communication over the past month. Items are rated to reflect
problem frequency using 5-point Likert scales ranging
from ‘never’ to ‘almost always’. The range of possible
HRQL scores was 0–100.
.

Outcomes
Outcomes were completed at two different time-points:
baseline (T1; after consent, before randomization) and
condition completion (8 weeks after randomization; T2).
They were completed online by participants through the
Research Electronic Data Capture (REDCap) secure
web-based system, hosted at The Hospital for Sick
Children. Study coordinators contacted participants via
telephone and e-mail to remind them to complete outcomes. All patient-reported outcome measures have
evidence of validity and reliability for adolescents with
arthritis.
Background outcomes
Participant characteristics were captured at baseline:
sociodemographic variables, JIA diagnosis and disease
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Exploratory outcomes
.

App engagement was measured using APEEE [27].
Frequencies of symptom Check-In completion and
interaction with the History feature were captured for
both groups. Frequency of user interaction with Goals,
Library and Community features were captured for
intervention participants only.

Sample size
Hertzog recommends that pilot studies should include
20–30 participants per group to examine feasibility of a
larger, fully powered trial [31]. We therefore planned to
randomize 60 adolescents to one of the two study
conditions.

https://academic.oup.com/rheumatology
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control (symptom tracking) condition. The allocation
ratio was 1:1. The trial is registered on ClinicalTrials.gov
with the identifier NCT02764346. The study was
approved by the locally responsible Research Ethics
Boards at each of the participating institutions.

Pilot randomized controlled trial

TABLE 1 Feature overview of the iCanCope program for adolescents with JIA by study condition
iCanCope feature

Description

Check-In

Both (i.e. attentioncontrol and intervention)

Daily symptom tracker for pain intensity, pain interference, mood, physical
activity, sleep quality and energy. Pain intensity was self-reported on a 0–
10 numerical rating scale with the anchors ‘no pain’ and ‘worst pain’.
Other symptom categories were captured via individual 5-point Likert
scale where a lower score indicated better function. Participants received
daily push notifications to complete a Check-In at a time of their choice.

History

Both

Interactive calendar interface with filters for different parameters from the
Check-In. Designed to allow users to view their historical symptom data
and understand trends.

Pain Areas

Both

Selectable body map [23] to capture pain location (body part), pain quality
(word descriptors) and pain triggers (word descriptors).

Inflammation Areas

Both

Selectable body map to capture areas of JIA inflammation.

Goals

Intervention only

Create and track personalized goals to improve JIA pain and function. Goals
could be created within the categories of physical activity, sleep, social,
mood and energy. Users could either write their own goal or customize
pre-populated goals within each category. Goals were encouraged to adhere to the SMART framework [24]. Each goal was structured as a single
sentence, such as: ‘Wind down an hour before bed by journaling’. Users
could view all of their active goals and mark goals as ‘complete’ when applicable. Specific goals were suggested to users based on their Check-In
data as per an app algorithm. For instance, if a user was reporting poor
mood, they would be pushed a mood-related goal to try.

Library

Intervention only

Comprised of approximately 100 articles. Each article was focussed on
JIA disease education, pain coping strategies (e.g. yoga exercises, belly
breathing), or disease self-management (e.g. strategies to remember to
take JIA medications). Articles contained a mixture of text, illustrations,
videos and audio-recordings. Each article was 300 words or less and
written at a grade 6–7 reading level. Specific articles were pushed to
users based on their Check-In data as per an app algorithm. For instance, if a user was reporting poor sleep, they would be pushed an article with advice for improving sleep.

Community

Intervention only

‘Question of the week’ style forum where users could post short answers
to questions posed by the app. Questions were designed to build a positive, supportive community of app users. They were written in consultation with patient partners (young people with persistent pain) on the
research team. Example questions: ‘what helps you to fall asleep?’;
‘what advice would you give your younger self?’; ‘what motivates you to
get moving?’ Users could post responses that were visible to all app
users or ‘favourite’ other people’s posts. The community was monitored
by the research team and users could also flag content that they found
inappropriate, if needed. Users were identified within the community by
nicknames only.

SMART: specific, measurable, achievable, realistic/relevant and timed.

Randomization and condition deployment

Blinding

Randomization was centrally controlled, concealed and
balanced by study centre (i.e. to control for centrespecific JIA education). A secure, web-based randomization service (www.randomize.net) was used for allocating participants to the study groups. Following
randomization, participants were sent standardized
instructions on how to download and access their
assigned app on their personal smartphone. A research
team member facilitated an app orientation with each
participant over the telephone. During orientation (15–
30 min), participants were guided through the app features and completed their first symptom Check-In.

Adolescents were blinded to their
group. Both groups received a
iCanCope app and equal attention
team. The statistician was blinded to
tion during the analysis.

https://academic.oup.com/rheumatology

assigned study
version of the
from the study
group identifica-

Statistical methods
Data were analysed using STATA version 15.1 (Stata
Statistical Software, StataCorp, College Station, TX,
USA, 2017). Descriptive statistics were used to describe
background characteristics of the sample.
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Study condition

Chitra Lalloo et al.

Preliminary effectiveness outcomes
As per an intent-to-treat approach, all participants were
analysed according to the study arm to which they were
randomized. A significance level of 0.05 was used for
the preliminary effectiveness outcomes of pain intensity,
pain-related activity limitations and HRQL. Linear mixed
models, adjusting for baseline values, were used to assess the effects of the intervention on outcomes of interest. Given the exploratory nature of the pilot trial, no
adjustments were made for multiple comparisons.
Exploratory outcomes
Descriptive statistics were used to summarize frequencies of app engagement across features.

Results
Participants
Recruitment was carried out between June 2017 and
April 2019. The Consolidated Standards of Reporting
Trials [34] (CONSORT) flow diagram detailing participant
enrolment, allocation, follow-up and analysis is provided
in Fig. 1. The randomized study sample was comprised
of 60 adolescents. Characteristics of the adolescent
sample, categorized by assigned study condition, are
provided in Table 2. Almost all participants (n ¼ 56;
93.3%) used a smartphone multiple times per day.

Primary outcomes: implementation
Accrual and attrition
Calculated rates of participant accrual and attrition
were:

200
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.

73 consented/129 approached (56.59%)
60 randomized/73 consented (82.19%)
8 lost to follow-up/60 randomized (13.3%)

Deployment of study conditions
The rates of successful app deployment for the intervention and attention-control conditions were: 25/29 (86%)
and 31/31 (100%), respectively.
Acceptability of study conditions
Both study conditions surpassed the threshold for sufficient acceptability. The mean (S.D.) acceptability scores
were 34.7 (S.D. 4.9) and 34.6 (S.D. 3.7) for intervention
and attention-control participants, respectively.
A majority of intervention participants (57%) were willing to use their assigned app for longer than 8 weeks (i.e.
the study period). The remainder of intervention participants were willing to use the app for: 4 weeks (4%) or
8 weeks (39%). Attention-control participants were willing
to use their assigned app for: 4 weeks (3%), 6 weeks
(7%), 8 weeks (48%) or longer than 8 weeks (41%).
Adherence to daily symptom tracking
The mean number of completed daily Check-Ins was
29.6 (S.D. 14.5) for intervention participants and 29.0 (S.D.
11.7) for attention-control participants. As per operational
definitions of adherence, intervention participants who
received the app (n ¼ 25) were distributed as follows: low
(3, 12%), low-moderate (8, 32%), high-moderate (9, 36%)
and high (5, 20%). Attention-control participants who
received the app (n ¼ 29) were distributed as follows: low
(3, 10%), low-moderate (10, 34.5%), high-moderate
(10, 34.5%) and high (6, 21%). Fig. 2 displays the total
number of participants who completed a Check-In as a
function of time, categorized by study group.
Overall, 16/25 (64%) intervention participants and 23/
29 (79%) attention-control participants accessed the
History function at least once during the 55-day study
period.
Supplementary
Fig.
S2,
available
at
Rheumatology online, displays the breakdown of views
for each symptom category within History according to
study group. The app is designed such that when users
open the History section, they are shown the pain intensity heat map by default. The total view count includes
users who opened the History section multiple times in
the same day or filtered between different symptoms
within the same viewing session.

Secondary outcomes: preliminary effectiveness
Fig. 3 depicts the observed changes in pain intensity outcomes. Both groups exhibited improvements in pain intensity over time. There was a 1.73-point reduction for
intervention participants and a 1.09-point reduction for
attention-control participants. These changes in pain intensity did not statistically differ between groups (P ¼ 0.24).
Supplementary Figs S3 and S4, available at
Rheumatology online, depict changes in pain-related

https://academic.oup.com/rheumatology
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Implementation outcomes
Accrual rates were calculated as follows: n consented/n
approached; n randomized/n consented. Attrition was
calculated as follows: n lost to follow-up/n randomized.
Lost to follow-up was defined as a participant who was
missing all outcome data after baseline. Thresholds for
acceptable accrual (randomized/consented) and attrition
rates were set at >70% and <20%, respectively, based
on previous work [32]. The rate of successful app deployment was calculated for each study group as: n
randomized/n logged into assigned app. Deployment
success was classified as low (50%), moderate (51–
80%) or high (81–100%). Descriptive statistics were
used to summarize data on acceptability and engagement. As per author recommendations [26], sufficient
acceptability was defined as 80% of the highest possible score on the Acceptability e-Scale (i.e. 32/40).
Adherence was operationally defined [33] as the relative
proportion of symptom Check-Ins that were completed
over the 55-day study period: ‘low adherence’ (24%;
<13 reports); ‘low-moderate adherence’ (25–49%; 14–
27 reports); ‘high-moderate adherence’ (50–75%; 28–41
reports); or ‘high adherence’ (76–100%; 42–55 reports).

Pilot randomized controlled trial

FIG. 1 CONSORT diagram [33]

Enrollment
Identified from clinic lists (n=1490)

Consented (n=73)

Downloaded from https://academic.oup.com/rheumatology/article/60/1/196/5866174 by guest on 08 August 2022

Assessed for eligibility (n=790)

Not approached (n=702)
Excluded by HCPs (n=89)
Staff away or missed patient (n=121)
No time to discuss research (n=15)
Not interested in research (n=47)
Transitioning out of care (n=7)
Appointment cancelled or missed (n=205)
Seen for other research studies (n=204)
No reason provided (n=114)
Excluded (n=657)
Pain not >3 on 0-10 NRS (n=568)
Unable to speak and read English (n=4)
Co-morbid psychiatric illness or cognitive
impairment (n=46)
No daily access to smartphone (n=8)
Enrolled in an intervention study (n=24)
Previous iCanCope participant (n=7)
Declined to participate (n=44)
Not interested (n=42)
Time commitment (n=2)
Lost to follow-up after approach (n=14)
Baseline not complete (n=13)

Randomized (n=60)

Allocation
Allocated to attention-control (n=31)
Received allocated condition (n=31)

Allocated to intervention (n=29)
Received allocated condition (n=25)
Did not receive allocated condition
o Did not complete app orientation (n=4)

Follow-Up
Lost to follow-up
o Did not complete endpoint questionnaires
(n=2)

Lost to follow-up
o Did not complete endpoint questionnaires
(n=6)

Analysis
Primary effectiveness outcome (pain
intensity) analysis (n=29)

Primary effectiveness outcome (pain
intensity) analysis (n=25)

CONSORT: Consolidated Standards of Reporting Trials; HCP: healthcare provider; NRS: numerical rating scale.
activity limitations and health-related quality of life outcomes, respectively. There were no significant changes
in pain-related activity limitations (P ¼ 0.650) or HRQL
(P ¼ 0.141–0.885). See Supplementary Table S1, available at Rheumatology online, for the regression output
for all preliminary effectiveness outcomes.

https://academic.oup.com/rheumatology

Exploratory outcome: engagement
Engagement with available app features among intervention and attention-control participants is summarized
in Table 3.
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TABLE 2 Adolescent demographic and disease characteristics
Characteristic

Intervention (n 5 29)

Attention-control (n 5 31)

15.0 (1.7)

14.9 (1.7)

15.1 (1.6)

47 (78.3)
13 (21.7)

23 (79.3)
6 (20.7)

24 (77.4)
7 (22.6)

2 (3.5)
2 (3.5)
1 (1.8)
1 (1.8)
1 (1.8)
6 (10.5)
3 (5.3)
1 (1.8)
40 (70.2)

1 (3.4)
0 (0.0)
1 (3.4)
0 (0.0)
1 (3.4)
4 (13.8)
2 (6.9)
0 (0.0)
20 (69.0)

1 (3.6)
2 (7.1)
0 (0.0)
1 (3.6)
0 (0.0)
2 (7.1)
1 (3.6)
1 (3.6)
20 (71.4)

3 (5.2)
9 (15.5)
5 (8.6)
14 (24.1)
3 (5.2)
7 (12.1)
12 (20.7)
3 (5.2)
2 (3.4)

1 (3.6)
5 (17.9)
1 (3.6)
9 (32.1)
2 (7.1)
3 (10.7)
5 (17.9)
1 (3.6)
1 (3.6)

2 (6.7)
4 (13.3)
4 (13.3)
5 (16.7)
1 (3.3)
4 (13.3)
7 (23.3)
2 (6.7)
1 (3.3)

36 (70.6)
15 (29.4)
6.0 (5.1)

17 (68.0)
8 (32.0)
6.5 (5.4)

19 (73.1)
7 (26.9)
5.5 (4.8)

Missing from analyses: race, n ¼ 3 (attention-control n ¼ 3); JIA category, n ¼ 2 (attention-control n ¼ 1, intervention n ¼ 1);
disease severity, n ¼ 9 (attention-control n ¼ 5, intervention n ¼ 4); duration of illness, n ¼ 5 (attention-control n ¼ 4, intervention n ¼ 1). PGA: Physician Global Assessment [27].

FIG. 2 Proportion of participants who completed a Check-In as a function of time, by study group
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Age in years, mean (S.D.)
Sex, n (%)
Female
Male
Race, n (%)
Aboriginal
Arab or West Asian
Black
Chinese
Filipino
Multi-racial
South Asian
South East Asian
White
JIA category, n (%)
Systemic
Oligoarthritis
Oligoarthritis—extended
Polyarthritis (RF–)
Polyarthritis (RFþ)
Psoriatic arthritis
Enthesitis-related arthritis
Undifferentiated
Other
Disease severity, n (%)
Low (0–3 PGA)
Moderate-to-severe(4–10 PGA)
Duration of illness in years, mean (S.D.)

Overall (N 5 60)

Pilot randomized controlled trial

FIG. 3 Linear mixed models for pain intensity data

Comparison with previous work

Lower scores indicate less pain. Thin lines represent
raw individual participant scores at baseline and endpoint. Thicker lines show overall fitted values in each
group based on the regression model.

TABLE 3 Engagement with available app features by study
group
App feature

Check-Ins
History
Pain areas
Inflammation Areas
Goals
Library
Community

Intervention
(n 5 25),
n (%)
25 (100)
16 (64)
17 (59)
13 (52)
11 (44)
12 (48)
10 (40)

Attentioncontrol
(n 5 29), n (%)
29 (100)
23 (79)
17 (59)
14 (48)
Feature not available
Feature not available
Feature not available

Discussion
Main findings
This study sought to evaluate the feasibility and preliminary effectiveness of the iCanCope pain selfmanagement program in adolescents with JIA. Our
results indicate that the iCanCope trial is feasible to implement as planned. Across study sites, local research
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A previous feasibility study was conducted to evaluate a
version of the iCanCope app for adolescents with chronic pain [33]. In that study, N ¼ 60 adolescents with
chronic pain were randomized to use an intervention or
attention-control version of iCanCope for 8 weeks. The
content of the chronic pain app was similar to the JIA
version, except that there was no body map for inflammation, and some library articles were disease specific.
Results from the chronic pain feasibility study were similar to the present JIA study. Both versions of the chronic
pain app were deployed with high success. Chronic
pain participants displayed similar levels of adherence
to the intervention and attention-control apps, with a
majority exhibiting moderate to high adherence.
Effectiveness of iCanCope in chronic pain-related health
outcomes is being evaluated in an ongoing full-scale
randomized controlled trial.

Engagement with self-management features
While participants in both groups exhibited similar adherence to Check-Ins, members of the attention-control
group were somewhat more likely to view their symptom
trends via the History feature. Conceivably, attentioncontrol participants may have engaged more strongly
with symptom tracking because it was the only feature
available in their proffered app. Although intervention participants had access to additional self-management features (i.e. Goals, Library, Community), only 40–44%
chose to engage with this additional app content. This
study evaluated the first iteration (i.e. version 1) of
iCanCope, which included some design elements
intended to promote engagement across features. For example, an internal algorithm was used to push suggested
content (i.e. Goals, Articles) to users based on their computed Check-In data. Given that fewer than half of intervention participants actually engaged with this content,
the next iteration of iCanCope will implement strategies
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staff were able to randomize 82% of those consented
and study attrition was <15%. Both study conditions
were deployed with high success as per operational definitions and were rated as highly acceptable by participants. Participants displayed similar levels of adherence
to the intervention and attention-control versions of the
app, with a majority exhibiting moderate to high adherence. Pain intensity improved in both groups by 1.73
points (intervention) and 1.09 points (attention-control),
respectively. These changes exceed the minimal clinically important difference for adolescents with persistent
pain, which is >1 point on a 0–10 NRS [35]. There were
no significant changes in pain-related activity limitations
or HRQL. Exploratory analyses indicated that participants exhibited varying levels of engagement with available app features.

Chitra Lalloo et al.

intended to boost engagement. First, the app homepage
will be redesigned to highlight daily messages and suggested content. Second, the app articles will be restructured to be shorter, use more playful language and
incorporate more images of the app character rather than
stock photos. Third, the History feature will be updated to
support customizable graphs of symptom data over week
and month views. Lastly, the content suggestion algorithm will be adjusted based on pilot data.

Study strengths

Study limitations
Given the lack of a third study arm, we cannot assess
the effect of iCanCope relative to usual care alone [36].
Although the reported study attrition aligns with previous
JIA studies [15, 37, 38], it nevertheless took 22 months
to randomize 60 adolescents. The pace of technology
change necessitates rapid methods of evaluation, otherwise risking app obsolescence by the time a trial is
complete [39]. Our research group is presently exploring
the open-source ResearchKit framework (Apple Inc.) as
a means to expand iCanCope recruitment from paediatric hospitals to include remote community-based enrolment [40]. Theoretically, the remote screening,
consenting and onboarding of trial participants through
ResearchKit may enhance future enrolment rates.

Future work
In the present study, participants who received either
version of the iCanCope app exhibited improvements in
pain intensity that exceeded the threshold of clinical importance [35]. These preliminary reductions in pain intensity warrant a future larger trial to evaluate program
effectiveness in improving JIA health outcomes. Further
work is also needed to explore how symptom tracking
alone may confer benefit to JIA patients. Conceivably,
the acts of symptom tracking and viewing of historical
trends may have prompted users to reflect on their
behaviours and make adjustments in their daily life (e.g.
prioritizing sleep). Future work will explore this possibility
and also collect comparator data from a ‘usual care’

204

Conclusions
The iCanCope pilot randomized controlled trial was
feasible to implement in a paediatric rheumatology setting. Both study apps were deployed successfully, acceptable and associated with moderate-to-high
adherence in most adolescents with JIA pain.
Preliminary reductions in pain intensity warrant a future
trial to evaluate the effectiveness of iCanCope in improving health outcomes in adolescents with JIA.
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